| First Author | Zheng H | Year | 2017 |
| Journal | Cancer Cell | Volume | 32 |
| Issue | 6 | Pages | 731-747.e6 |
| PubMed ID | 29232552 | Mgi Jnum | J:357903 |
| Mgi Id | MGI:6103047 | Doi | 10.1016/j.ccell.2017.11.002 |
| Citation | Zheng H, et al. (2017) Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell 32(6):731-747.e6 |
| abstractText | Bone metastasis is a major health threat to breast cancer patients. Tumor-derived Jagged1 represents a central node in mediating tumor-stromal interactions that promote osteolytic bone metastasis. Here, we report the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11). In addition to its inhibitory effect on bone metastasis of Jagged1-expressing tumor cells, 15D11 dramatically sensitizes bone metastasis to chemotherapy, which induces Jagged1 expression in osteoblasts to provide a survival niche for cancer cells. We further confirm the bone metastasis-promoting function of osteoblast-derived Jagged1 using osteoblast-specific Jagged1 transgenic mouse model. These findings establish 15D11 as a potential therapeutic agent for the prevention or treatment of bone metastasis. |
